About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

[Today's key financial data and events: Friday, June 20, 2025] ① To be determined Russian President Putin's speech ② 07:01 UK June Gfk Consumer Confidence Index ③ 07:30 Japan May Core CPI Annual Rate ④ 09:00 China's one-year loan market benchmark rat

2025-06-20

[Today's key financial data and events: Friday, June 20, 2025] ① To be determined Russian President Putin's speech ② 07:01 UK June Gfk Consumer Confidence Index ③ 07:30 Japan May Core CPI Annual Rate ④ 09:00 China's one-year loan market benchmark rate to June 20 ⑤ 14:00 Germany May PPI monthly rate ⑥ 14:00 UK May seasonally adjusted retail sales monthly rate ⑦ 14:40 Bank of Japan Governor Kazuo Ueda's speech ⑧ 20:30 Canada April retail sales monthly rate ⑨ 20:30 US June Philadelphia Fed Manufacturing Index ⑩ 22:00 Eurozone June Consumer Confidence Index Preliminary Value ⑪ 22:00 US May Conference Board Leading Indicator Monthly Rate ⑫ 01:00 the next day US total number of oil rigs for the week ending June 20 ⑬ The next day at 02:30, New York crude oil July futures completed the last transaction on the floor

Other News
2025-06-20

Senior Iranian official: We need to listen to the "initiative" of the three European countries on the nuclear issue.

Senior Iranian official: We need to listen to the "initiative" of the three European countries on the nuclear issue.
2025-06-20

[Bank of America raises Sino Biopharmaceutical target to HK$5.9 Reiterates buy] Bank of America Securities issued a report stating that Sino Biopharmaceutical (01177.HK) recently announced that a licensing transaction will be implemented, and the com

[Bank of America raises Sino Biopharmaceutical target to HK$5.9 Reiterates buy] Bank of America Securities issued a report stating that Sino Biopharmaceutical (01177.HK) recently announced that a licensing transaction will be implemented, and the company expects the sales proportion of innovative drugs to increase to more than 50% this year and reach 60% by 2027. The growth momentum is driven by the company's "internal research and development + external licensing" dual-engine strategy. In addition, the company recently received approval from the National Medical Products Administration for its Phase III clinical trial of TQC3721 for the treatment of chronic obstructive pulmonary disease (COPD). The bank took TQC3721's revenue forecast into consideration and raised Sino Biopharmaceutical's total revenue forecast for 2027 by 1%; the target price was raised from HK$5.1 to HK$5.9, and the "buy" rating was reiterated because the company's product pipeline is progressing smoothly.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2025 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.

Web Design by YSD